Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › SENORES

SENORES

Senores Pharmaceuticals Limited
Micro-capPharma ↗

What the six lenses say about SENORES — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹1497.5
2026-09-08
VWAP · 1Y anchor
₹981
+52.6% from VWAP
P/E · TTM
59.8×
TTM EPS ₹25.0
52-week range
94%
position low→high
RSI(14)
58
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How SENORES’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
8.0
avg conviction decile
Leadership
Leader
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD10100›

The actual numbers

Price vs VWAP (1y)+52.6%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+38.9%
Price vs 50-EMA+7.7%
RSI(14)58
RS vs Nifty 500 · 3M+44.3%
RS vs sector · 3M+38.2%
52-week range94%
Volume vs 30d avg1.57×
Volume vs 60d avg1.16×
ATR(14) · volatility65.1
Bollinger width · vol contraction0.096
FundamentalD1077›

The actual numbers

Return on equity (ROE)13.1%
Operating margin28.3%
Net margin18.9%
Revenue growth · YoY+62.3%
EPS growth · YoY+56.5%
Debt / equity0.37×

Full 8-quarter history in the financials table below.

ValuationD22›

The actual numbers

P/E (TTM)59.8×
TTM EPS₹25.0
52-week range94%
CatalystD844›

The actual numbers

Earnings & momentum50
Capital actions6
Governance126

Every filing in the corporate-announcements panel below.

FlowD650›

The actual numbers

Promoter holding45.8%
Delivery · 30d avg43.8%
Up/down-day asymmetry1.3pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D10 + D6 ) ÷ 2 = 8.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
95
Conviction score 95/100 · avg-decile strength 8.0/10
Conviction score95/100›
TechnicalD10›
FundamentalD10›
ValuationD2›
CatalystD8›
FlowD6›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+5.3pp
+5.8pp
+16.2pp
+45.9pp
+102.1pp
+104.9pp
Nifty 500
Broad-market baseline
+5.3pp
+5.8pp
+15.1pp
+44.3pp
+96.3pp
+99.7pp
Sector
Own-sector index
—
—
+12.3pp
+38.2pp
+83.2pp
+78.9pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

SENORES daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
1497.50+69.10

Relative strength

RS vs baseline · rebased to 100

SENORES ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
259.55+13.02

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)80101103114138162171175
↳ change QoQ—+26.3%+2.0%+10.7%+21.1%+17.4%+5.6%+2.3%
EBITDA (₹cr)2123311934505047
EBITDA margin26.3%22.8%29.9%16.7%24.6%30.9%29.2%26.9%
PAT (₹cr)1113161821303437
↳ change QoQ—+18.2%+26.4%+9.6%+16.7%+42.9%+13.3%+8.8%
Net margin13.8%12.9%16.0%15.8%15.2%18.5%19.9%21.1%
EPS (₹)3.233.865.043.874.287.036.876.86
D/E————————
YoY growth · Mar '26Revenue +53.5% YoYPAT +105.6% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 27 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 Aug '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 Aug '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 24 Aug '26
    LOWgovernance
    Giving guarantees/indemnity/ becoming a surety for third party
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 20 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 3 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 Jul '26
    LOWgovernance
    Statement of deviation(s) or variation(s) under Reg. 32
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 Jul '26
    LOWgovernance
    Statement of deviation(s) or variation(s) under Reg. 32
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 Jul '26
    LOWgovernance
    Monitoring Agency Report
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds SENORES

Mutual funds holding SENORES (10)

FundWeightAUM ₹crGrade
HSBC Multi Cap Reg Gr0.74%6,068
TrustMF Small Cap Reg Gr1.39%2,860
Mahindra Manulife Lrg & Md cap Reg Gr1.98%2,827
Bajaj Finserv Small Cap Reg Gr1.00%2,364
Bajaj Multi Asst Allc Reg Gr0.76%1,943
Mahindra Manulife Bal Advtg Reg Gr1.28%917
WhiteOak Capital Phrm and Hlthcr Reg Gr0.85%825
TRUSTMF Multi Cap Regular Growth0.90%681
Bajaj Finserv Consumption Reg Gr1.67%620
TRUSTMF Mid Cap Reg Gr1.22%429

ETFs holding SENORES (0)

No tracked ETF holds SENORES ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma